Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the...
October 15 2020 - 8:00AM
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage
biopharmaceutical company that is genetically engineering red blood
cells to create an entirely new class of cellular medicines, today
announced that the company will present preclinical data supporting
its lead clinical oncology program, RTX-240, at the upcoming
Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary
Annual Meeting. The meeting is being held virtually from November
9-14, 2020. RTX-240 is an allogeneic, off-the-shelf Red Cell
Therapeutic™ that is engineered to mimic the human immune system by
stimulating adaptive and innate immunity to generate an anti-tumor
immune response.
“At SITC, we plan to present preclinical data supporting our
lead clinical oncology program, RTX-240, demonstrating that RTX-240
promotes T cell and NK cell activation and expansion in vitro and
in vivo,” said Laurence Turka, M.D., chief scientific officer of
Rubius Therapeutics. “We are continuing to enroll patients in the
Phase 1/2 clinical trial of RTX-240 for the treatment of patients
with relapsed/refractory or locally advanced solid tumors, and we
have a cleared Investigational New Drug application for the
treatment of patients with relapsed/refractory acute myeloid
leukemia for which we are actively recruiting patients.”
All posters will be made available at the beginning of the
virtual meeting on Monday, November 9, 2020, at 9:00 a.m. ET and
throughout the poster presentation sessions:
Abstract Title: RTX-240, an Allogeneic
Engineered Red Blood Cell Expressing 4-1BBL and IL-15TP, Promotes
NK Cell Functionality In Vitro and In
VivoCategory: Novel Single-Agent
ImmunotherapiesSession Dates and
Times: November 11-14,
2020, 9:00 a.m. - 5:00 p.m. ETPoster
Number: 703
About RTX-240RTX-240 is an allogeneic,
off-the-shelf Red Cell Therapeutic™ that is engineered to mimic the
human immune system by stimulating adaptive and innate immunity to
generate an anti-tumor immune response. RTX-240 simultaneously
presents hundreds of thousands of copies of the costimulatory 4-1BB
ligand (4-1BBL) and the trans-presented cytokine interleukin-15
(IL-15TP) in their native forms on the cell surface to activate and
expand NK and T cells. 4-1BBL is a costimulatory molecule that can
drive T and NK cell proliferation and activation and interferon
gamma (IFNγ) production. IL-15 is a cytokine that bridges innate
and adaptive immunity by promoting NK and T cell proliferation and
NK cell cytotoxicity. IL-15TP is a fusion of IL-15 and IL-15
receptor alpha.
About Rubius TherapeuticsRubius Therapeutics is
a clinical-stage biopharmaceutical company developing a new class
of medicines called Red Cell Therapeutics™. The Company’s
proprietary RED PLATFORM® was designed to genetically engineer and
culture Red Cell Therapeutics™ that are selective, potent and
off-the-shelf allogeneic cellular therapies for the potential
treatment of several diseases across multiple therapeutic areas.
Rubius’ initial focus is to advance RCT™ product candidates for the
treatment of cancer and autoimmune diseases by leveraging two
distinct therapeutic modalities — potent cell-cell interaction and
tolerance induction. Rubius Therapeutics’ manufacturing site was
recently named 2020 Top 5 Best Places to Work in Rhode Island among
medium-sized companies by Providence Business News. For more
information, visit www.rubiustx.com, follow us on Twitter or
LinkedIn or like us on Facebook.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, statements regarding the, our
expectations regarding the therapeutic potential of our Red Cell
Therapeutics, including RTX-240 for the treatment of
relapsed/refractory or locally advanced solid tumors or acute
myeloid leukemia and our strategy, business plans and focus,
including our plans to present preclinical data at the SITC 35th
Annual Meeting. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management’s current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the
development of our Red Cell Therapeutic product candidates and
their therapeutic potential and other risks identified in our SEC
filings, including our Annual Report on Form 10-K for the year
ended December 31, 2019, and subsequent filings with the SEC. We
caution you not to place undue reliance on any forward-looking
statements, which speak only as of the date they are made. We
disclaim any obligation to publicly update or revise any such
statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward-looking statements. Any
forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent date. We
explicitly disclaim any obligation to update any forward-looking
statements.
Contacts:InvestorsLori
MelançonVice President, Corporate Communications and Investor
Relations+1 (617) 949-5296lori.melancon@rubiustx.com
Media Marissa HanifyDirector, Corporate
Communicationsmarissa.hanify@rubiustx.com
Dan Budwick1AB+1 (973) 271-6085dan@1abmedia.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jul 2023 to Jul 2024